Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
Department of Radiology, Sahlgrenska University Hospital, Göteborg, Sweden.
Clin Endocrinol (Oxf). 2021 Jun;94(6):956-967. doi: 10.1111/cen.14425. Epub 2021 Feb 9.
Somatostatin receptors (SSTRs) are potential targets for detecting pituitary neuroendocrine tumours (PitNETs) that can be visualized effectively with Ga-labelled PET tracers. With this study, we have evaluated the diagnostic properties of such a tracer, Ga-DOTATOC, in patients with hormone-producing PitNETs before and after surgery.
DESIGN/METHODS: This prospective case-control study presents preoperative positron emission tomography (PET) and histopathological data in 18 patients with somatotroph (n = 8), corticotroph (n = 7) and thyrotroph (n = 3) PitNETs. Patients were scanned pre- and postoperatively with Ga-DOTATOC PET. For the postoperative part of the study, patients with gonadotroph tumours (n = 7) were also included. Fifteen pituitary healthy controls underwent the same protocol once. The maximum standard uptake value (SUV ) was analysed in manually outlined regions around the tumour in patients and around the pituitary gland in controls. specimens were collected during surgery in subjects for assessment of adenohypophyseal tumour cell type and the SSTR expression.
Thyrotroph tumours showed higher uptake (median SUV 41.1; IQR 37.4-60.0) and corticotroph tumours lower uptake (SUV 6.8; 2.6-9.3) than normal pituitary gland (SUV 13.8; 12.1-15.5). The uptake in somatotroph tumours (SUV 15.9; 11.6-19.7) was similar to the uptake in the pituitary gland. There was a strong correlation between SUV and SSTR2 expression (r = .75 (P < .01)). In the postoperative evaluation, PET was able to correlate tracer uptake with biochemical cure and noncure in patients with an abnormal postoperative magnetic resonance image and a preoperative tumour uptake SUV > 13.8.
Ga-DOTATOC PET can be used to detect thyrotroph tumours in the pre- and postoperative imaging assessment. Corticotroph tumours had a significantly lower uptake compared to the pituitary gland but without a distinct increased tumour uptake the clinical postoperative value is limited.
生长抑素受体 (SSTR) 是检测垂体神经内分泌肿瘤 (PitNET) 的潜在靶点,这些肿瘤可以通过 Ga 标记的 PET 示踪剂有效地可视化。本研究评估了这种示踪剂[68Ga]-DOTATOC 在术前和术后分泌激素的 PitNET 患者中的诊断特性。
这是一项前瞻性病例对照研究,纳入了 18 例生长激素(n=8)、促皮质激素(n=7)和促甲状腺激素(n=3)PitNET 患者的术前正电子发射断层扫描 (PET) 和组织病理学数据。患者在术前和术后均接受[68Ga]-DOTATOC PET 扫描。对于研究的术后部分,还纳入了 7 例促性腺激素肿瘤患者。15 例垂体健康对照者也接受了相同的方案。手动勾画肿瘤周围和对照组垂体周围的最大标准摄取值 (SUV) 进行分析。在手术中采集受试者的腺垂体肿瘤细胞类型和 SSTR 表达评估样本。
促甲状腺激素肿瘤的摄取量较高(中位数 SUV 41.1;IQR 37.4-60.0),促皮质激素肿瘤的摄取量较低(SUV 6.8;2.6-9.3),低于正常垂体(SUV 13.8;12.1-15.5)。生长激素肿瘤的摄取量(SUV 15.9;11.6-19.7)与垂体摄取量相似。SUV 与 SSTR2 表达之间存在很强的相关性(r=.75(P<.01))。在术后评估中,PET 能够将示踪剂摄取与生化治愈和未治愈相关联,患者术后磁共振成像异常且术前肿瘤摄取 SUV>13.8。
[68Ga]-DOTATOC PET 可用于术前和术后成像评估中检测促甲状腺激素肿瘤。与垂体相比,促皮质激素肿瘤的摄取量明显较低,但如果肿瘤摄取量没有明显增加,则其临床术后价值有限。